AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City